Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: Lack of influence of carcinogen or testosterone treatment

Cancer Science

Volumn 94, Issue 2, 2003, Pages 153-157

  Cho, Young Man ^a   Takahashi, Satoru ^a   Asamoto, Makoto ^a   Suzuki, Shugo ^a   Inaguma, Shingo ^a   Hokaiwado, Naomi ^a   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; 2',3 DIMETHYL 4 BIPHENYLAMINE; CARCINOGEN; METHYLNITROSOUREA; PROBASIN; TESTOSTERONE; VIRUS T ANTIGEN;

ADOLESCENT; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CARCINOGENESIS; CASTRATION; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE DISEASE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RAT; TRANSGENIC ANIMAL;

ADENOCARCINOMA; AGE FACTORS; AMINOBIPHENYL COMPOUNDS; ANDROGEN ANTAGONISTS; ANDROGEN-BINDING PROTEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CARCINOGENS; DISEASE PROGRESSION; DRUG IMPLANTS; ETHINYL ESTRADIOL; HETEROZYGOTE; IMIDAZOLES; KI-67 ANTIGEN; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM PROTEINS; ORCHIECTOMY; PHENOTYPE; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; TESTOSTERONE; TONGUE NEOPLASMS;

EID: 0037648687     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01412.x     Document Type: Article

References (34)

1. Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol 2002; 20: 3-9.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
3. Tominaga S. Cancer incidence in Japanese in Japan, Hawaii, and western United States. Natl Cancer Inst Monogr 1985; 69: 83-92.
4. Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 2001; 39: 219-26.
5. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocrinol Rev 1987; 8: 338-62.
6. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
7. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18: 52-74.
8. Shirai T, Fukushima S, Ikawa E, Tagawa Y, Ito N. Induction of prostate carcinoma in situ at high incidence in F344 rats by a combination of 3,2′-dimethyl-4-aminobiphenyl and ethinyl estradiol. Cancer Res 1986; 46: 6423-6.
9. Ito N, Shirai T, Tagawa Y, Nakamura A, Fukushima S. Variation in tumor yield in the prostate and other target organs of the rat in response to varied dosage and duration of administration of 3,2′-dimethyl-4-aminobiphenyl. Cancer Res 1988; 48: 4629-32.
10. Shirai T, Sano M, Imaida K, Takahashi S, Mori T, Ito N. Duration dependent induction of invasive prostatic carcinomas with pharmacological dose of testosterone propionate in rats pretreated with 3,2′-dimethyl-4-aminobiphenyl and development of androgen-independent carcinomas after castration. Cancer Lett 1994; 83: 111-6.
11. Asamoto M, Hokaiwado N, Cho Y-M, Takahashi S, Ikeda Y, Imaida K, Shirai T. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001; 61: 4693-700.
12. Asamoto M, Hokaiwado N, Cho YM, Ikeda Y, Takahashi S, Shirai T. Metastasizing neuroblastomas from taste buds in rats transgenic for the simian virus 40 large T antigen under control of the probasin gene promoter. Toxicol Pathol 2001; 29: 363-8.
13. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-43.
14. Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 1998; 36: 59-63.
15. Sullivan CS, Pipas JM. T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis. Microbiol Mol Biol Rev 2002; 66: 179-202.
16. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56: 4387-9.
17. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57: 846-9.
18. Mashimo T, Watabe M, Hirota S, Hosobe S, Miura K, Tegtmeyer PJ, Rinker-Shaeffer CW, Watabe K. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998; 95: 11307-11.
19. Duriez C, Falette N, Cortes U, Moyret-Lalle C, Puisieux A. Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene 2000; 19: 2461-4.
20. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687-91.
21. Wiedenmann B, Kuhn C, Schwechheimer K, Waldherr R, Raue F, Brandeis WE, Kommerell B, Franke WW. Synaptophysin identified in metastases of neuroendocrine tumors by immunocytochemistry and immunoblotting. Am J Clin Pathol 1987; 88: 560-9.
22. Ermisch B, Schwechheimer K. Protein gene product (PGP) 9.5 in diagnostic (neuro-) oncology. An immunomorphological study. Clin Neuropathol 1995; 14: 130-6.
23. Isaacs W, Kainu T. Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol Rev 2001; 23: 36-41.
24. Stuart GR, Holcroft J, de Boer JG, Glickman BW. Prostate mutations in rats induced by the suspected human carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5b]-pyridine. Cancer Res 2000; 60: 266-8.
25. Masui T, Shirai T, Imaida K, Hirose M, Futakuchi M, Tatematsu M, Ito N. Ki-ras mutations with frequent normal allele loss versus absence of p53 mutations in rat prostate and seminal vesicle carcinomas induced with 3,2′-dimethyl-4-aminobiphenyl. Mol Carcinog 1995; 13: 21-6.
26. Condon MS, Kaplan LAE, Crivello JF, Horton L, Bosland MC. Multiple pathways of prostate carcinogenesis analyzed by using cultured cells isolated from rats treated with N-methyl-N-nitrosourea and testosterone. Mol Carcinog 1999; 25: 179-86.
27. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 2002; 62: 2281-6.
28. Kawana Y, Komiya A, Ueda T, Nihei N, Kuramochi H, Suzuki H, Yatani R, Imai T, Dong JT, Yoshie O, Barrett JC, Isaacs JT, Shimazaki J, Ito H, Ichikawa T. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 1997; 32: 205-13.
29. Shirai T, Takahashi S, Mori T, Imaida K, Futakuchi M, Ye S-H, Prins GS, Ito N. Immunohistochemically demonstrated androgen receptor expression in the rat prostate during carcinogenesis induced by 3,2′-dimethyl-4-aminobiphenyl with or without testosterone. Urol Oncol 1995; 1: 263-8.
30. Takahashi S, Inaguma S, Sakakibara M, Cho YM, Suzuki S, Ikeda Y, Cui L, Shirai T. DNA methylation in the androgen receptor gene promoter in rat prostate cancers. Prostate 2002; 52: 82-8.
31. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000; 164: 3-9.
32. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000; 88: 3009-14.
33. Prins GS, Sklarew RJ, Pertschuk LP. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol 1998; 159: 641-9.
34. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687-97.